David Heydt, MD
Anatomic Pathology · Silver Spring, MDNPI 1194971622
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Roche Diagnostics Corporation accounts for 72.4% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $67, 3.8 times the $18 reported in 2019.
Across 14 payments — averaging $19.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diagnostics Corporation$200
- Indivior Inc.$25
- Meridian Bioscience Inc.$19
- Leica Microsystems Inc.$18
- Werfen USA LLC$14
What the payments were for
- Food & beverage$276100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Diagnostics Corporation | 9 | $200 |
| Indivior Inc. | 1 | $25 |
| Meridian Bioscience Inc. | 2 | $19 |
| Leica Microsystems Inc. | 1 | $18 |
| Werfen USA LLC | 1 | $14 |
How this compares
$276 in reported general payments places this provider in the 75th percentile of 39 anatomic pathology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $3,490 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 23 | $3,162 |
| Dicyclomine Hcl | 15 | $614 |
| Gabapentin | 12 | $358 |
| Cyclobenzaprine Hcl | 22 | $305 |
| Amlodipine Besylate | 20 | $283 |
| Clonidine Hcl | 17 | $266 |
| Trazodone Hcl | 14 | $233 |
| Atorvastatin Calcium | 11 | $219 |
| Hydroxyzine Pamoate | 17 | $137 |
| Hydrochlorothiazide | 13 | $77 |
| Carvedilol | 13 | $68 |
| Metoprolol Tartrate | 12 | $59 |
Paid to pharmacies, not to this prescriber.
Other anatomic pathology in Silver Spring
- Debora GagnetenSilver Spring$204K
- Aaron AuerbachSilver Spring$123
- Peter IlleiBaltimore$160K
- Renu VirmaniGaithersburg$52K
- Tamara LotanBaltimore$17K
- Ashley CiminoBaltimore$11K
- Alexander BarasBaltimore$6K
- Michael ChuiBaltimore$5K
- Aaron JamesBaltimore$825
- Tehmina AliBeltsville$753
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.